NZ337125A - 5,6,7-trisubstituted-4-amino-pyrido[2,3-d]pyrimidine compounds useful for inhibiting adenosine kinase - Google Patents

5,6,7-trisubstituted-4-amino-pyrido[2,3-d]pyrimidine compounds useful for inhibiting adenosine kinase

Info

Publication number
NZ337125A
NZ337125A NZ337125A NZ33712598A NZ337125A NZ 337125 A NZ337125 A NZ 337125A NZ 337125 A NZ337125 A NZ 337125A NZ 33712598 A NZ33712598 A NZ 33712598A NZ 337125 A NZ337125 A NZ 337125A
Authority
NZ
New Zealand
Prior art keywords
amino
pyrimidine
phenyl
pyrido
compound
Prior art date
Application number
NZ337125A
Other languages
English (en)
Inventor
Shripad S Bhagwat
Richard J Perner
Yu Gui Gu
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NZ337125A publication Critical patent/NZ337125A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ337125A 1997-04-16 1998-04-13 5,6,7-trisubstituted-4-amino-pyrido[2,3-d]pyrimidine compounds useful for inhibiting adenosine kinase NZ337125A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84348497A 1997-04-16 1997-04-16
PCT/US1998/007201 WO1998046604A1 (en) 1997-04-16 1998-04-13 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds

Publications (1)

Publication Number Publication Date
NZ337125A true NZ337125A (en) 2001-06-29

Family

ID=25290123

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ337125A NZ337125A (en) 1997-04-16 1998-04-13 5,6,7-trisubstituted-4-amino-pyrido[2,3-d]pyrimidine compounds useful for inhibiting adenosine kinase

Country Status (19)

Country Link
EP (1) EP0975633A1 (ja)
JP (1) JP2001520654A (ja)
KR (1) KR20010006462A (ja)
CN (1) CN1252069A (ja)
AR (1) AR012437A1 (ja)
AU (1) AU741033B2 (ja)
BG (1) BG103853A (ja)
BR (1) BR9809056A (ja)
CA (1) CA2286592A1 (ja)
CO (1) CO4940470A1 (ja)
HU (1) HUP0001443A3 (ja)
IL (1) IL131617A0 (ja)
NO (1) NO995035L (ja)
NZ (1) NZ337125A (ja)
PL (1) PL336265A1 (ja)
SK (1) SK140099A3 (ja)
TR (1) TR199902550T2 (ja)
WO (1) WO1998046604A1 (ja)
ZA (1) ZA983175B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057040A1 (en) * 2000-02-03 2001-08-09 Abbott Laboratories 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
ATE305303T1 (de) 2001-02-12 2005-10-15 Hoffmann La Roche 6-substituierte pyridopyrimidine
CN107744520A (zh) * 2017-10-25 2018-03-02 南京多宝生物科技有限公司 嘧啶类化合物在制备促进小肠蠕动药物中的应用
CN112209924B (zh) * 2019-07-09 2022-04-05 中国科学院天津工业生物技术研究所 选择性腺苷a1受体拮抗剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB774094A (en) * 1953-01-02 1957-05-08 Wellcome Found Improvements in or relating to pyrimidine compounds
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds

Also Published As

Publication number Publication date
AU7108098A (en) 1998-11-11
AR012437A1 (es) 2000-10-18
CA2286592A1 (en) 1998-10-22
SK140099A3 (en) 2000-05-16
JP2001520654A (ja) 2001-10-30
BR9809056A (pt) 2000-08-01
IL131617A0 (en) 2001-01-28
WO1998046604A1 (en) 1998-10-22
NO995035L (no) 1999-12-15
PL336265A1 (en) 2000-06-19
NO995035D0 (no) 1999-10-15
CO4940470A1 (es) 2000-07-24
AU741033B2 (en) 2001-11-22
HUP0001443A2 (hu) 2000-10-28
TR199902550T2 (xx) 2000-04-21
BG103853A (en) 2000-06-30
HUP0001443A3 (en) 2001-01-29
EP0975633A1 (en) 2000-02-02
KR20010006462A (ko) 2001-01-26
CN1252069A (zh) 2000-05-03
ZA983175B (en) 1998-10-21

Similar Documents

Publication Publication Date Title
JP5227032B2 (ja) プロテインキナーゼの阻害剤として有用なピロロピリミジン
US5665721A (en) Heterocyclic substituted cyclopentane compounds
WO2000023444A1 (en) 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
KR20080080584A (ko) ｃ-Ｍｅｔ의 억제제 및 이의 용도
US8481538B2 (en) Heterocyclic inhibitors of c-Met and uses thereof
JP2008528705A5 (ja)
JP2014513078A (ja) パーキンソン病の治療方法及び治療用組成物
EP0989986A1 (en) 5,7-disubstituted 4-aminopyrido 2,3-d]pyrimidine compounds and their use as adenosine kinase inhibitors
US20110135603A1 (en) Inhibitors of phosphatidylinositol 3-kinase
TW202003496A (zh) 一種新穎磷酸肌醇3 - 激酶抑制劑及其製備方法和用途
WO2005058315A1 (en) Novel heterocyclic compounds as ikk2 inhibitors with anti-hbv activity
AU744528B2 (en) 6,7-disubstituted-4-aminopyrido(2,3-d)pyrimidine compounds
US6030969A (en) 5,6,7-trisubstituted-4-aminopyrido[2,3-D] pyrimidine compounds
NZ337125A (en) 5,6,7-trisubstituted-4-amino-pyrido[2,3-d]pyrimidine compounds useful for inhibiting adenosine kinase
WO2001057040A1 (en) 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
JP2013506691A (ja) ホスファチジルイノシトール３−キナーゼのピラゾール阻害薬
CZ350899A3 (cs) 5,6,7-trisubstituované-4-aminopyrido-[2,3- D]pyrimidinové sloučeniny
MXPA99009512A (en) 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds
CZ339399A3 (cs) 5,7-Disubstituované 4-aminopyrido[2.3- D]pyrimidinové sloučeniny a jejich použití jako inhibitorů adenosin kinasy
CZ360199A3 (cs) Sloučeniny 6,7-disubstituovaného-4- aminopyrido [2,3-dJ pyrimidinu

Legal Events

Date Code Title Description
PSEA Patent sealed